Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease

被引：1
|
作者：
Hirano-Lotman, Yui [1 ]
Ishida, Yoshihiro [1 ]
Endo, Yuichiro [1 ]
Ogawa, Seishi [2 ]
Kabashima, Kenji [1 ]
机构：
[1] Kyoto Univ, Dept Dermatol, Grad Sch Med, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Pathol & Tumor Biol, Kyoto, Japan
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
CHEMOTHERAPY; PERTUZUMAB;
D O I：
10.2340/actadv.v103.9399
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Role of Fcγ receptors in HER2-targeted breast cancer therapy
    Musolino, Antonino
    Gradishar, William J.
    Rugo, Hope S.
    Nordstrom, Jeffrey L.
    Rock, Edwin P.
    Arnaldez, Fernanda
    Pegram, Mark D.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [42] The role of PP2A in innate resistance to HER2-targeted therapy
    Conlon, N.
    McDermott, M.
    Crown, J.
    O'Donovan, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
    Ariga, Shin
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
  • [44] OUTCOMES OF PATIENTS WITH HER2-POSITIVE BREAST CANCER METASTATIC TO BRAIN TREATED WITH HER2-TARGETED SYSTEMIC THERAPY AND STEREOTACTIC RADIOSURGERY
    Shumway, John
    Torras, Marina
    Reeder-Hayes, Katherine
    Jolly, Trevor
    Dees, Elizabeth
    Ray, Emily
    Muss, Hyman
    Carey, Lisa
    Shen, Colette
    NEURO-ONCOLOGY, 2021, 23 : 41 - 41
  • [45] No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
    Veitch, Zachary
    Ribnikar, Domen
    Tilley, Derek
    Tang, Patricia A.
    King, Karen
    Bedard, Philippe L.
    Lupichuk, Sasha
    Cescon, David W.
    BRITISH JOURNAL OF CANCER, 2022, 126 (06) : 881 - 888
  • [46] No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
    Zachary Veitch
    Domen Ribnikar
    Derek Tilley
    Patricia A. Tang
    Karen King
    Philippe L. Bedard
    Sasha Lupichuk
    David W. Cescon
    British Journal of Cancer, 2022, 126 : 881 - 888
  • [47] HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
    La Salvia, Anna
    Lopez-Gomez, Victoria
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 29 - 38
  • [48] HER2-targeted antibody drug conjugates for ovarian cancer therapy
    Jiang, Jing
    Dong, Lihou
    Wang, Lei
    Wang, Ling
    Zhang, Jing
    Chen, Fang
    Zhang, Xiuli
    Huang, Min
    Li, Shenjun
    Ma, Weiwei
    Xu, Qiaoyu
    Huang, Changjiang
    Fang, Jianmin
    Wang, Chunhua
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 93 : 274 - 286
  • [49] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
    Murthy, Rashmi Krishna
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana J.
    Murray, James L.
    Koenig, Kimberly Higginbotham
    Green, Marjorie C.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Booser, Daniel J.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Outcomes of Patients With HER2-Positive Breast Cancer Metastatic to Brain Treated With HER2-Targeted Systemic Therapy and Stereotactic Radiosurgery
    Shumway, J. W.
    Torras, M.
    Hayes, K. Reeder
    Jolly, T.
    Dees, E. C.
    Ray, E. M.
    Carey, L. A.
    Shen, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E580 - E580
12345